| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
We first demonstrated the involvement of Cav3.2 T-type calcium channels in hydrogen sulfide-induced facilitation of nociception. We then found that, in rats with L5 spinal nerve injury, the activation of Cav3.2 by endogenous hydrogen sulfide was involved in the maintenance of hyperalgesia/allodynia, and Cav3.2 was upregulated, suggesting that the hydrogen sulfide/Cav3.2 pathway should be a therapeutic target for treatment of neurogenic pain.
|
